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Background: Canada’s pandemic H1N1 influenza A (pH1N1) outbreak led to a high burden of critical illness. Our
objective was to describe the incidence of AKI (acute kidney injury) in these patients and risk factors for AKI, renal
replacement therapy (RRT), and mortality.
Methods: From a prospective cohort of critically ill adults with confirmed or probable pH1N1 (16 April 2009–12
April 2010), we abstracted data on demographics, co-morbidities, acute physiology, AKI (defined by RIFLE criteria for
Injury or Failure), treatments in the intensive care unit, and clinical outcomes. Univariable and multivariable logistic
regression analyses were used to evaluate the associations between clinical characteristics and the outcomes of AKI,
RRT, and hospital mortality.
Results: We included 562 patients with pH1N1-related critical illness (479 [85.2%] confirmed, 83 [14.8%] probable]:
mean age 48.0 years, 53.4% female, and 13.3% aboriginal. Common co-morbidities included obesity, diabetes, and
chronic obstructive pulmonary disease. AKI occurred in 60.9%, with RIFLE categories of Injury (23.0%) and Failure
(37.9%). Independent predictors of AKI included obesity (OR 2.94; 95%CI, 1.75-4.91), chronic kidney disease (OR 4.50;
95%CI, 1.46-13.82), APACHE II score (OR per 1-unit increase 1.06; 95%CI, 1.03-1.09), and PaO2/FiO2 ratio (OR per 10-unit
increase 0.98; 95%CI, 0.95-1.00). Of patients with AKI, 24.9% (85/342) received RRT and 25.8% (85/329) died.
Independent predictors of RRT were obesity (OR 2.25; 95% CI, 1.14-4.44), day 1 mechanical ventilation (OR 4.09; 95% CI,
1.21-13.84), APACHE II score (OR per 1-unit increase 1.07; 95% CI, 1.03-1.12), and day 1 creatinine (OR per 10 μmol/L
increase, 1.06; 95%CI, 1.03-1.10). Development of AKI was not independently associated with hospital mortality.
Conclusion: The incidence of AKI and RRT utilization were high among Canadian patients with critical illness due to
pH1N1.
Keywords: Acute kidney injury, Renal replacement therapy, Influenza, Critical illness, Mortality, Resource utilizationBackground
In the spring of 2009, the world experienced a pandemic
due to novel swine-origin influenza A (pH1N1) virus, with
more than 17,000 deaths [1–6]. In Canada, there were two
major waves of pH1N1 in the spring and fall of 2009 that
led to 8,678 hospitalizations, of which 1,473 (17.0%) re-
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reproduction in any medium, provided the or2010, there were approximately 428 deaths (4.9%; 12.7 per
million population) attributable to pH1N1 infection, the
12th highest pH1N1-attributable mortality worldwide [7].
Of particular concern among pH1N1 patients was the
high risk of ICU admission for respiratory failure [7,8].
Several studies have described the impact of pH1N1 on
ICU resources, with an emphasis on respiratory failure,
mechanical ventilation, and extracorporeal life support
(ECLS) [9,10]. Fewer studies have focused on non-
pulmonary organ dysfunction, specifically acute kidney
injury (AKI) and its resource implications. AKI com-
monly accompanies critical illness and independentlyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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opment of new chronic kidney disease (CKD) among survi-
vors [11,12]. Recently, reports have described the incidence
and outcomes of AKI among critically ill adult and pediatric
pH1N1 patients [13–28]. Many studies, however, were lim-
ited by design (case reports [14,17,20,22,24,28] or small case
series [13,15,18,21,27]), small sample size [16,19,25], or
single-center enrollment [13,15,16,18,21]. There have been
few larger scale prospective multi-center cohorts [19,23,26],
none of which described the Canadian pandemic.
Accordingly, we examined a prospective multi-centre
Canadian cohort of critically ill patients and confirmed
or probable pH1N1 infection [2] to primarily describe
the incidence and severity of AKI and secondarily deter-
mine the rates of RRT utilization along with risk factors
for AKI, RRT, and mortality.
Methods
This study was approved by the Research Ethics Board
at Sunnybrook Health Sciences Centre, Toronto on 30
April 2009 (file #130-2009), and at all participating sites.
All Research Ethics Boards waived the requirement for
individual informed consent. The reporting of this study
follows recent guidelines [29].
Study design, setting, and participants
This cohort study is a secondary analysis of prospectively col-
lected data from a multi-centre inception cohort of all adults
(age >18 years), admitted to any of 51 Canadian ICUs, with
confirmed or probable influenza A (pH1N1)-related critical
illness, from 16 April 2009 to 12 April 2010 [2]. Members of
the Canadian Critical Care H1N1 Collaborative are listed in
Additional file 1. The 51 ICUs that agreed to collect data for
this study constituted a subset of the 286 Canadian ICUs that
provide mechanical ventilation (R. Fowler, personal commu-
nication). Data on a subset of 50 patients in this cohort, all
fromManitoba, Canada, were published previously [27].
Data collection
Data from patients’ medical records were captured on
standardized case-report forms, as described elsewhere
[2]. Briefly, we collected data on dates and times of hos-
pital and ICU admission and discharge, demographics, co-
morbid diseases, acute physiology, laboratory parameters,
illness severity (APACHE II [Acute Physiology and
Chronic Health Evaluation II] [30] and SOFA [Sequential
Organ Failure Assessment] [31] scores), treatment inten-
sity (including mechanical ventilation, inotrope and vaso-
pressor support, and RRT, with each determined on days
1, 3, 7, 14, and 28 of ICU admission), and vital status at
hospital discharge. The comorbid condition of obesity was
defined as body mass index ≥30 kg/m2. Diagnostic tests,
including scheduled serum creatinine levels, were not
mandated by the study protocol.Cohort definitions
Patients with pH1N1 were included if confirmed or prob-
able according to case definitions of the World Health
Organization and the Canadian National Microbiology La-
boratory [32]. Critical illness was defined by: 1) admission to
an ICU and either 2) receipt of mechanical ventilation (inva-
sive or non-invasive) or 3) receipt of inotrope or vasopressor
infusion [2]. Chronic kidney disease (CKD) was defined as
pre-morbid baseline serum creatinine ≥1.5 times the upper
limit of normal. End-stage kidney disease was defined as
outpatient dialysis dependence preceding ICU admission.
Outcome definitions
The primary outcome was AKI, defined according to the RI-
FLE (Risk; Injury; Failure; Loss; End-stage kidney disease)
classification scheme [33]. Patients were classified according
to the worst RIFLE category achieved while in ICU, with
RIFLE categories Injury and Failure used to define AKI. Cat-
egories were determined on days 1, 3, 7, 14, and 28 of ICU
admission, using both creatinine and 24-hour urine output
on those days, with baseline glomerular filtration rate esti-
mated as 75 ml/min/1.73 m2 [33]. Because this assumption
may overestimate the incidence of AKI, we determined
RIFLE categories using two additional approaches in sensi-
tivity analyses: (1) assuming ICU day 1 creatinine as the
baseline, and (2) assuming the lowest creatinine in the ICU
as the baseline, except for patients who received RRT, who
were all assumed to be in the Failure category. Both ap-
proaches would tend to underestimate the incidence of AKI
because any creatinine measured in the ICU in a patient not
on RRT is unlikely to be lower than baseline.
Secondary outcomes included utilization of RRT (any
of continuous renal replacement therapy, slow low-
efficiency hemodialysis, intermittent hemodialysis); hos-
pital mortality; and lengths of ICU and hospital stay.
Statistical analysis
The study sample size was based on the number of patients
with pH1N1-related critical illness admitted to a study ICU
during the period of pH1N1 activity. Continuous variables
were summarized as means (standard deviations) or medians
(quartile 1 [Q1] - quartile 3 [Q3]) as appropriate and categor-
ical variables as proportions. We used Student’s two-sample
t-test orWilcoxon rank sum test to compare continuous vari-
ables and chi-square or Fisher’s exact test for categorical vari-
ables. Univariable and multivariable logistic regression were
used to evaluate associations between clinical characteristics
and the outcomes of AKI, RRT, and hospital mortality. Age
and sex were included in all models, AKI was forced into the
mortality model, and other explanatory variables were in-
cluded if p ≤0.2 by univariable analysis. We used univariable
analyses to screen potential variables because we anticipated
having too few events to include all variables in the initial
model. All selected variables initially entered in the
Table 1 Comparison of participants included versus excluded due to missing data
Characteristic Overall Included Excluded P
value(n = 671) (n = 562) (n = 109)
Age (yr) 47.9 (15.2) 48.0 (15.0) 47.1 (16.4) 0.55
Female sex 363 (54.1) 300 (53.4) 63 (57.8) 0.40
Ethnicity (n=652, 555, 97)
White/Caucasian 378 (58.0) 327 (58.9) 51 (52.6) 0.41
Unknown/Mixed/Other 143 (21.9) 117 (21.1) 26 (26.8)
Aboriginal 85 (13.0) 74 (13.3) 11 (11.3)
Asian 46 (7.1) 37 (6.7) 9 (9.3)
Any co-morbidity 607 (90.5) 513 (91.3) 94 (86.2) 0.10
Obesity 167 (24.9) 150 (26.7) 17 (15.6) 0.01
Diabetes mellitus 170 (25.3) 146 (26.0) 24 (22.0) 0.38
Chronic obstructive pulmonary disease 119 (17.7) 98 (17.4) 21 (19.3) 0.65
Alcohol abuse 83 (12.4) 74 (13.2) 9 (8.3) 0.15
Chronic kidney disease 56 (8.4) 48 (8.5) 8 (7.3) 0.68
H1N1 status
Confirmed 574 (85.5) 479 (85.2) 95 (87.2) 0.60
Probable 97 (14.5) 83 (14.8) 14 (12.8)
Days of symptoms pre-hospital (n = 635, 532, 103) 4.0 (2.0-7.0) 4.0 (2.0-7.0) 3.0 (1.0-6.0) 0.01
Days of symptoms pre-ICU (n = 653, 549, 104) 5.0 (3.0-8.0) 5.0 (3.0-8.0) 4.5 (2.5-7.0) 0.04
Day 1 support, physiology, and laboratory values
APACHE II score (n = 594, 508, 86) 20.8 (9.8) 21.1 (9.2) 19.1 (13.1) 0.19
SOFA score (n = 411, 361, 50) 11.2 (3.7) 11.2 (3.8) 10.9 (3.6) 0.61
Invasive mechanical ventilation (n = 652, 553, 99) 431 (66.1) 384 (69.4) 47 (47.5) <0.0001
Inotrope or vasopressor 281 (41.9) 251 (44.7) 30 (27.5) 0.0009
Mean arterial pressure (mmHg) (n = 613, 522, 91) 74.1 (18.7) 74.4 (18.9) 72.5 (17.4) 0.37
Heart rate (beats/min) (n = 504, 433, 71) 104.1 (24.0) 104.5 (24.1) 101.5 (23.3) 0.33
Temperature (°C) (n = 472, 405, 67) 37.6 (1.3) 37.6 (1.2) 37.5 (1.8) 0.48
PaO2/FiO2 (n = 570, 496, 74) 160 (120) 153 (96) 212 (215) 0.02
CK (U/L) (n = 270, 230, 40) 272 (91-776) 293 (91-835) 224 (87-663) 0.41
CK > 5000 IU/L (n = 270, 230, 40) 15 (5.6) 13 (5.7) 2 (5.0) 1.00
WBC (109/L) (n = 471, 409, 62) 9.7 (6.5) 9.5 (6.5) 10.6 (7.0) 0.24
Albumin (g/L) (n = 315, 275, 40) 26.6 (7.2) 26.2 (7.0) 28.7 (8.0) 0.04
Platelets (109/L) (n = 608, 520, 88) 190 (96) 188 (96) 204 (95) 0.16
Urea (mmol/L) (n = 89, 76, 13) 10.2 (19.7) 10.5 (21.0) 8.4 (9.4) 0.56
Creatinine (μmol/L) (n = 626, 537, 89) 125 (120) 124 (120) 131 (119) 0.59
Urine output (mL/24 hr) (n = 489, 431, 58) 1440 (1082) 1439 (1055) 1446 (1278) 0.97
Interventions (ICU day 1, 3, 7, 14, or 28)
Renal replacement therapy (n = 670, 561, 109) 91 (13.6) 85 (15.2) 6 (5.5) 0.007
Invasive mechanical ventilation (n = 669, 562, 107) 568 (84.9) 499 (88.8) 69 (64.5) <0.0001
Inotropes or vasopressors 373 (55.6) 339 (60.3) 34 (31.2) <0.0001
Antiviral treatment 620 (92.4) 530 (94.3) 90 (82.6) <0.0001
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Table 1 Comparison of participants included versus excluded due to missing data (Continued)
Outcome
Days of ICU stay (n = 640, 539, 101) 11.0 (6.0-19.0) 11.0 (7.0-20.0) 5.0 (2.0-13.0) <0.0001
Days of hospital stay (n = 626, 523, 103) 18.0 (11.0-34.0) 19.0 (12.0-35.0) 12.0 (5.0-24.0) <0.0001
Hospital mortality (n = 649, 545, 104) 142 (21.9) 113 (20.7) 29 (27.9) 0.11
Patients described in this table were excluded because of insufficient data to determine the RIFLE classification. For each variable, we specify (n) with data if it
differs from the total in the first row. Categorical data are presented as n (%) and continuous data as mean (SD) or median (Q1-Q3).
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data were missing for more than 15% of the study sample.
Interaction termswere not considered. There was no evidence
ofmulti-collinearity in any of themultivariablemodels (all cor-
relations <0.8). We examined model calibration using the
Hosmer-Lemeshow test; no model demonstrated lack of
goodness-of-fit. We considered p < 0.05 to be statistically sig-
nificant. All analyses were performed using SAS version 9.2
(SAS Institute Inc, Cary, USA).
Results
Overall, 756 consecutive critically ill patients with con-
firmed or probable pH1N1 entered the cohort. For this
study, 194 (25.7%) participants were excluded due to
missing eligibility criteria (n = 2) or age (n = 1), pediatric
status (n = 62), pre-admission dialysis dependence (n =
20), or insufficient data to assign a RIFLE category (n =Table 2 Baseline characteristics of critically ill pH1N1 patients
Characteristic Overall
(n = 562)
Age (yr) 48.0 (15.0)
Female sex 300 (53.4)





Any co-morbidity 513 (91.3)
Obesity 150 (26.7)
Diabetes mellitus 146 (26.0)
Chronic obstructive pulmonary disease 98 (17.4)
Alcohol abuse 74 (13.2)




Days of symptoms pre-hospital (n = 532, 326, 206) 4.0 (2.0-7.0)
Days of symptoms pre-ICU (n = 549, 336, 213) 5.0 (3.0-8.0)
AKI is defined by the RIFLE Injury or Failure categories and no AKI by the RIFLE Non
Categorical data are presented as n (%) and continuous data as mean (SD) or medi
in the first row.109). The remaining 562 (74.3%) patients (479 [85.2%]
with confirmed and 83 [14.8%] with probable pH1N1)
were included. To investigate selection bias, we compared
the study sample and patients excluded due to insufficient
data to assign RIFLE category (n = 109). Excluded patients
had a shorter duration of symptoms before hospital and
ICU admission, were less likely to be obese, and had lower
treatment intensity, with fewer receiving mechanical ven-
tilation, antiviral therapy, and RRT; they also had shorter
lengths of ICU and hospital stay (Table 1).
Patients had a mean (SD) age of 48.0 (15.0) years,
53.4% were female, 13.3% were aboriginal, and 91.3%
had at least one co-morbid disease, with obesity (26.7%),
diabetes mellitus (26.0%), and chronic obstructive pul-
monary disease (17.4%) being most common (Table 2).
Patients had high illness severity and burden of organ
dysfunction (APACHE II score 21.1 [9.2]; day 1 SOFA, stratified by AKI
AKI No AKI P
value(n = 342) (n = 220)
49.1 (15.1) 46.4 (14.8) 0.03
177 (51.8) 123 (55.9) 0.34
0.23
204 (60.7) 123 (56.2)
68 (20.2) 49 (22.4)
47 (14.0) 27 (12.3)
17 (5.1) 20 (9.1)
316 (92.4) 197 (89.6) 0.24
118 (34.5) 32 (14.6) <0.0001
107 (31.3) 39 (17.7) 0.0003
56 (16.4) 42 (19.1) 0.41
41 (12.0) 33 (15.0) 0.30
44 (12.9) 4 (1.8) <0.0001
291 (85.1) 188 (85.5) 0.90
51 (14.9) 32 (14.6)
4.0 (2.0-7.0) 4.0 (2.0-7.0) 0.67
5.0 (3.0-8.0) 5.0 (3.0-8.0) 0.66
e or Risk categories.
an (Q1-Q3). For each variable, we specify (n) with data if it differs from the total
Table 3 Clinical course and outcomes of critically ill pH1N1 patients, stratified by AKI
Overall AKI No AKI P
value(n = 562) (n = 342) (n = 220)
Day 1 support, physiology, and laboratory values
APACHE II score (n = 508, 306, 202) 21.1 (9.2) 23.0 (9.6) 18.1 (7.6) <0.0001
SOFA score (n = 361, 216, 145) 11.2 (3.8) 12.0 (3.8) 9.7 (3.2) <0.0001
Invasive mechanical ventilation (n = 553, 338, 215) 384 (69.4) 241 (71.3) 143 (66.5) 0.23
Inotrope or vasopressor 251 (44.7) 164 (48.0) 87 (39.6) 0.05
Mean arterial pressure (mmHg) (n = 522, 315, 207) 74 (19) 73 (19) 76 (19) 0.14
Heart rate (beats/min) (n = 433, 262, 171) 104 (24) 106 (25) 102 (22) 0.07
Temperature (°C) (n = 405, 244, 161) 37.6 (1.2) 37.6 (1.3) 37.7 (1.2) 0.84
PaO2/FiO2 (n = 496, 299, 197) 153 (96) 143 (94) 167 (98) 0.006
CK (U/L) (n = 230, 137, 93) 293 (91-835) 320 (102-949) 206 (90-681) 0.08
CK > 5000 IU/L (n = 230, 137, 93) 13 (5.7) 10 (7.3) 3 (3.2) 0.19
WBC (109/L) (n = 409, 243, 166) 9.6 (6.5) 9.7 (6.8) 9.3 (6.0) 0.45
Albumin (g/L) (n = 275, 167, 108) 26.2 (7.0) 26.1 (7.1) 26.4 (7.0) 0.77
Platelets (109/L) (n = 520, 313, 207) 188 (96) 184 (95) 194 (96) 0.26
Urea (mmol/L) (n = 76, 44, 32) 10.5 (21.0) 14.4 (26.9) 5.1 (2.8) 0.03
Creatinine (μmol/L) (n = 537, 326, 211) 124 (120) 155 (144) 76 (31) <0.0001
Urine output (mL/24 hr) (n = 431, 270, 161) 1439 (1055) 1070 (939) 2058 (946) <0.0001
Clinical course and outcomes
Invasive mechanical ventilation 499 (88.8) 313 (91.5) 186 (84.6) 0.01
Inotropes or vasopressors 339 (60.3) 222 (64.9) 117 (53.2) 0.006
Antiviral treatment 530 (94.3) 326 (95.3) 204 (92.7) 0.20
Renal replacement therapy (n = 561, 342, 219) 85 (15.2) 85 (24.9) 0 <0.0001
Days of hospital stay (n = 523, 319, 204) 19.0 (12.0-35.0) 20.0 (12.0-40.0) 17.0 (12.0-30.0) 0.13
Days of ICU stay (n = 539, 325, 214) 11.0 (7.0-20.0) 12.0 (7.0-24.0) 10.0 (6.0-16.0) 0.002
Hospital mortality (n = 545, 329, 216) 113 (20.7) 85 (25.8) 28 (13.0) 0.0003
AKI is defined by the RIFLE Injury or Failure categories and no AKI by the RIFLE None or Risk categories.
Categorical data are presented as n (%) and continuous data as mean (SD) or median (Q1-Q3). For each variable, we specify (n) with data if it differs from the total
in the first row.
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mechanical ventilation and 44.7% received an inotrope
or vasopressor (Table 3).
Incidence, characteristics, and predictors of AKI
Of 562 study patients, 342 (60.9%) developed AKI (worst
RIFLE category Injury [n = 129, 23.0%] or Failure [n =
213, 37.9%]; Table 4). Using the 2 alternate approaches
to estimate baseline kidney function, the incidence of
AKI (Table 4) was lower (49.9%) if ICU day 1 creatinine
was assumed as baseline and similar (61.2%) if the low-
est ICU creatinine was assumed as baseline, with those
receiving RRT designated as RIFLE Failure.
In univariable analyses, AKI patients were more likely
to be older (49.1 [15.1] vs. 46.4 [14.8] years, p = 0.03),
obese (34.5% vs. 14.6%, p < 0.0001), diabetic (31.1% vs.
17.7%, p = 0.0003) and have CKD (12.9% vs. 1.8%,p < 0.0001) (Table 2). Similarly, AKI patients were also more
severely ill on ICU day 1 (Table 3) compared to those
without AKI, with higher APACHE II scores (23.0 [9.6]
vs. 18.1 [7.6], p < 0.0001), SOFA scores (12.0 [3.8] vs. 9.7
[3.2], p < 0.0001), and worse PaO2/FiO2 ratios (143 [94]
vs. 167 [98], p = 0.006). AKI patients had greater eleva-
tions in serum creatinine (155 [144] vs. 76 [31] μmol/L,
p < 0.0001) and serum urea (14.4 [26.9] vs. 5.1 [2.8]
mmol/L, p = 0.03) and lower 24-hour urine output
(1070 [939] vs. 2058 [946] mL, p < 0.0001) on the first
day of ICU admission.
Multivariable logistic regression (Table 5) showed that
obesity (OR 2.94; 95% CI, 1.75-4.91), CKD (OR 4.50; 95%
CI, 1.46-13.82), and increasing APACHE II score (OR per
unit 1.06; 95% CI, 1.03-1.09) were independently associ-
ated with AKI. Higher PaO2/FiO2 ratio was protective (OR
per 10-unit increase 0.98; 95% CI, 0.95-1.00).
Table 4 Incidence of acute kidney injury in critically ill pH1N1 patients using different definitions of baseline renal
function
Primary analysis, with baseline glomerular filtration rate estimated as 75 ml/min/1.73 m2 Incidence Hospital
mortality1, 2(n = 562)
No AKI 220 (39.1) 28/216 (13.0)
None 181 (32.2) 21/178 (11.8)
Risk 39 (6.9) 7/38 (18.4)
AKI 342 (60.9) 85/329 (25.8)
Injury 129 (23.0) 20/125 (16.0)
Failure 213 (37.9) 65/204 (31.9)
Renal replacement therapy, n = 561 85 (15.1) 26/84 (31.0)
Injury 3 (0.5%) 3/3 (100)
Failure 82 (14.6%) 26/81 (31.0%)
Sensitivity analysis 1, assuming that first available serum creatinine is the baseline n = 537
No AKI 269 (50.1) 45/262 (17.2)
None 221 (41.2) 26/217 (12.0)
Risk 48 (8.9) 19/45 (42.2)
AKI 268 (49.9) 64/259 (24.7)
Injury 253 (47.1) 61/244 (25.0)
Failure 15 (2.8) 3/15 (20.0)
Sensitivity analysis 2, assuming that lowest observed serum creatinine at any time is the baseline n = 562
No AKI 218 (38.8) 27/214 (12.6)
None 194 (34.5%) 25/191 (13.1)
Risk 24 (4.2%) 2/23 (8.7)
AKI 344 (61.2) 86/331 (26.0)
Injury 118 (21.0%) 15/114 (13.2)
Failure3 226 (40.2%) 71/217 (32.7)
Data are presented as n (%).
1 Denominators differ from the incidence column due to missing survival status (17/562 patients).
2 In the primary analysis, mortality differed significantly across the 4 RIFLE categories of None, Risk, Injury, and Failure (p < 0.0001) and across the categories of
Risk, Injury, and Failure (p = 0.003).
3 For this analysis, patients who received RRT are assumed to have ‘Failure’.
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Patients with AKI were more likely to receive invasive
mechanical ventilation and inotropes or vasopressors in the
ICU, and had longer ICU but similar hospital length of stay
(Table 3). Eighty-five patients received RRT (24.9% of
patients with AKI and 15.1% of entire cohort); 82 achieved
maximum RIFLE category of Failure and 3 achieved max-
imum RIFLE category of Injury prior to RRT initiation.
Multivariable logistic regression showed that independent
predictors of receiving RRT (Table 6) were obesity (OR
2.25; 95% CI, 1.14-4.44), day 1 mechanical ventilation (OR
4.09; 95% CI, 1.21-13.84), and increasing APACHE II score
(OR per unit, 1.07; 95% CI, 1.03-1.12) and day 1 creatinine
(OR per 10 μmol/L, 1.06; 95% CI, 1.03-1.10).
Hospital survival status was available for 545 patients
(97.0%). When stratified by AKI severity (Table 4), crude
mortality differed (p < 0.0001) across RIFLE categories
of None (21/178, 11.8%), Risk (7/38, 18.4%), Injury (20/125, 16.0%), and Failure (65/204, 31.9%). Mortality in the
AKI and no AKI categories was similar among methods
used to estimate baseline renal function (Table 4).
Univariable analysis showed that AKI was associated
with hospital mortality, but this association was no lon-
ger significant after multivariable adjustment (OR 1.35;
95% CI, 0.74-2.48; Table 7). Independent predictors of
increased hospital mortality were age (OR 1.02 per year;
95% CI, 1.00-1.04) and APACHE II score (OR 1.05 per
unit; 95% CI, 1.01-1.08), whereas higher PaO2/FiO2 ratio
(OR 0.95 per 10 units; 95% CI, 0.92-0.99) and platelets
(OR 0.92 per 10 × 109/L; 95% CI, 0.89-0.96) on day 1
were associated with lower mortality.
Discussion
Summary of major findings
We performed a prospective multi-centre cohort study
in representative ICUs from across Canada of patients
Table 5 Logistic regression model for acute kidney injury in critically ill pH1N1 patients
Variable AKI No AKI Crude OR P
value
Adjusted OR P
valuen = 342 n = 220 (95% CI) (95% CI)
H1N1 details, demographics, and comorbidities
Confirmed H1N1 291 (85.1) 188 (85.5) 0.97 (0.60-1.57) 0.90
Age (yr) 49.1 (15.1) 46.4 (14.8) 1.01 (1.00-1.02) 0.03 1.00 (0.98-1.02) 0.98
Female sex 177 (51.8) 123 (55.9) 0.85 (0.60-1.19) 0.34 0.86 (0.56-1.32) 0.50
Ethnicity (n = 555, 336, 219)
White/Caucasian (reference) 204 (60.7) 123 (56.2) 1.00 1.00
Unknown/Mixed/ Other 68 (20.2) 49 (22.4) 0.84 (0.54-1.29) 0.42 0.80 (0.46- 1.39) 0.43
Aboriginal 47 (14.0) 27 (12.3) 1.05 (0.62-1.77) 0.86 1.01 (0.52-1.94) 0.98
Asian 17 (5.1) 20 (9.1) 0.51 (0.26-1.02) 0.06 0.82 (0.35-1.89) 0.64
Obesity 118 (34.5) 32 (14.6) 3.10 (2.00-4.79) <0.0001 2.94 (1.75-4.91) <0.0001
Diabetes mellitus 107 (31.3) 39 (17.7) 2.11 (1.40-3.20) 0.0004 1.61 (0.96-2.69) 0.07
Chronic obstructive pulmonary disease 56 (16.4) 42 (19.1) 0.83 (0.53-1.29) 0.41
Alcohol abuse 41 (12.0) 33 (15.0) 0.77 (0.47-1.26) 0.30
Chronic kidney disease 44 (12.9) 4 (1.8) 7.97 (2.82-22.5) <0.0001 4.50 (1.46-13.82) 0.009
Day 1 support, physiology, and laboratory values
APACHE II score (n = 508, 306, 202) 23.0 (9.6) 18.1 (7.6) 1.07 (1.04-1.09) <0.0001 1.06 (1.03- 1.09) <0.0001
Invasive mechanical ventilation (n = 553, 338, 215) 241 (71.3) 143 (66.5) 1.25 (0.86-1.81) 0.23
Inotrope or vasopressor 164 (48.0) 87 (39.6) 1.41 (1.00-1.99) 0.05 1.29 (0.82-2.01) 0.27
Mean arterial pressure (mmHg) (n = 522, 315, 207) 73.4 (18.7) 75.9 (19.2) 0.93 (0.85-1.02) 0.14 0.95 (0.85-1.06) 0.32
PaO2/FiO2 (n = 496, 299, 197) 143 (94) 167 (98) 0.97 (0.96-0.99) 0.007 0.98 (0.95- 1.00) 0.04
Platelets (109/L) (n = 520, 313, 207) 184 (95) 194 (96) 0.99 (0.97-1.01) 0.26
Categorical data are presented as n (%) and continuous data as mean (SD). Heart rate, temperature, creatine kinase, WBC, albumin, and urea were excluded due
to a high proportion of missing data. SOFA score was excluded because it was highly collinear with APACHE II score (Pearson r = 0.6). Urine output and creatinine
were excluded because they were used to define the outcome. For each variable, we specify n when it differs from the totals in the first row. The final model
included 442 patients and did not have evidence of lack of goodness of fit (p = 0.40). ORs for continuous variables refer to an increment of 1 unit (age, APACHE II)
or 10 units (mean arterial pressure, PaO2/FiO2, platelets).
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http://www.biomedcentral.com/1471-2369/14/123with confirmed or probable pH1N1 infection, the major-
ity of whom were mechanically ventilated, to describe
the incidence of AKI, rate of RRT utilization, and associ-
ated outcomes. AKI was common, complicating the
course of 60.9% of patients. Most developed more severe
forms of AKI, defined by RIFLE categories of Injury and
Failure. Moreover, 24.9% of those with AKI, or 15.1% of
the entire pH1N1 cohort, received RRT. In general, we
found that AKI was more likely to occur in older patients
with a higher burden of comorbid disease, specifically
obesity, diabetes mellitus, and CKD. In addition, those de-
veloping AKI presented with higher acuity of illness,
greater burden of organ dysfunction and showed worse
kidney function early after ICU admission compared to
those not developing AKI. Finally, pH1N1 patients whose
course was complicated by AKI received far greater inten-
sity (i.e. invasive mechanical ventilation, vasoactive sup-
port, and RRT) and duration of support in ICU, with
comparable length of hospital stay and mortality.Strengths and limitations
Our study has several strengths. It provides prospective,
multicentre, nationally representative data of critically ill
patients with pH1N1 and describes the incremental bur-
den associated with development of AKI. Our study also
provides complementary data to other large observa-
tional studies from distinct geographic regions on the at-
tributable burden of AKI in pH1N1-related critical
illness [1,5,23,25]. However, we also recognize our
study’s limitations. First, despite a large cohort, data on
kidney function were missing or unavailable for 16.2% of
patients. These excluded patients were less severely ill
and less intensively treated, and thus we may have
overestimated the incidence of AKI. Second, we assumed
normal baseline renal function among included patients
and may thus have overestimated the incidence of AKI,
but the incidence of AKI and mortality among these pa-
tients did not dramatically change in sensitivity ana-
lyses that would be expected to underestimate the
Table 6 Logistic regression model for renal replacement therapy in critically ill H1N1 patients
Variable RRT No RRT Crude OR P
value
Adjusted OR P
valuen = 85 n = 476 (95% CI) (95% CI)
Demographics and comorbidities
Age (yr) 46.2 (13.1) 48.4 (15.3) 0.99 (0.98-1.01) 0.21 0.98 (0.96-1.00) 0.07
Female sex 43 (50.6) 256 (53.8) 0.88 (0.55-1.40) 0.59 1.81 (0.91-3.58) 0.09
Ethnicity (n = 554, 85, 469)
White/Caucasian (reference) 56 (65.9) 271 (57.8) 1.00 1.00
Unknown/Other 19 (22.4) 97 (20.7) 0.95 (0.54-1.68) 0.85 0.53 (0.22-1.28) 0.16
Aboriginal 6 (7.1) 68 (14.5) 0.43 (0.18-1.03) 0.06 0.40 (0.13-1.20) 0.10
Asian 4 (4.7) 33 (7.0) 0.59 (0.20-1.7) 0.33 1.11 (0.31-3.95) 0.88
Obesity 33 (38.8) 117 (24.6) 1.95 (1.20-3.16) 0.007 2.25 (1.14-4.44) 0.02
Diabetes mellitus 23 (27.1) 123 (25.8) 1.06 (0.63-1.79) 0.81
Chronic obstructive pulmonary disease 5 (5.9) 93 (19.5) 0.26 (0.10-0.65) 0.004 0.26 (0.06-1.20) 0.08
Alcohol abuse 10 (11.8) 64 (13.5) 0.86 (0.42-1.75) 0.67
Chronic kidney disease 15 (17.7) 33 (6.9) 2.88 (1.49-5.57) 0.002 0.85 (0.28-2.57) 0.78
Day 1 support, physiology, and laboratory values
APACHE II score (n = 507, 80, 427) 27.6 (9.2) 19.8 (8.6) 1.10 (1.07-1.13) <0.0001 1.07 (1.03-1.12) 0.0009
Invasive mechanical ventilation (n = 552, 85, 467) 72 (84.7) 311 (66.6) 2.78 (1.49-5.17) 0.001 4.09 (1.21-13.84) 0.02
Inotrope or vasopressor 44 (51.8) 206 (43.3) 1.41 (0.89-2.23) 0.15 0.78 (0.37-1.61) 0.50
Mean arterial pressure (mmHg) (n = 521, 79, 442) 70.4 (16.9) 75.2 (19.2) 0.87 (0.76-0.995) 0.04 0.97 (0.81–1.16) 0.75
PaO2/FiO2 (n = 495, 76, 419) 132 (95) 156 (96) 0.97 (0.94-1.00) 0.046 0.97 (0.93-1.01) 0.16
Platelets (109/L) (n = 519, 76, 443) 164 (84) 192 (96) 0.97 (0.94-0.995) 0.02 0.99 (0.95-1.03) 0.64
Creatinine (μmol/L) (n = 536, 79, 457) 233 (185) 105 (93) 1.07 (1.05-1.09) <0.0001 1.06 (1.03-1.10) <0.0001
Categorical data are presented as n (%) and continuous data as mean (SD). Heart rate, temperature, creatine kinase, WBC, albumin, urea, and urine output were
excluded due to a high proportion of missing data. SOFA score was excluded because it was highly collinear with APACHE II (Pearson r = 0.6). For each variable,
we specify n when it differs from the totals in the first row. The final model included 411 patients and did not have evidence of lack of goodness of fit (p = 0.17).
ORs for continuous variables refer to an increment of 1 unit (age, APACHE II), 10 units (mean arterial pressure, PaO2/FiO2, platelets, creatinine), or 100 units
(urine output).
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http://www.biomedcentral.com/1471-2369/14/123incidence. Only 24-hr daily urine output, as opposed
to hourly urine output, was available for determin-
ation of RIFLE category. Therefore, we modified our
criteria as previously reported [34], possibly under-
estimating the incidence of AKI by missing patients
with transient decrements in urine output. Third, we
may not have accounted for additional confounding
variables in the associations of clinical characteristics
and AKI, RRT, and hospital mortality. In particular,
we did not have information on the type or amount
of fluid resuscitation, non–H1N1-related infections,
or other nephrotoxins. We also did not collect data
on the modality, mode, or dose of RRT, although
none of these has been shown to consistently influ-
ence mortality [35–37].
Comparison with prior literature
In our study, the incidence of AKI complicating the
course of pH1N1-related critical illness in Canada was
higher than reported from Spain (17.7%) [23], South
Korea (22.6%) [19], Australia and New Zealand (34.0%)[26], United States (42.0%) [16], and similar to that
reported in Argentina (51.0%) [24,25]. Many risk factors
for AKI identified in our cohort, specifically older age
[15,19], diabetes [19,23,26], CKD [16,19,26], and illness
severity [13,19,23,25,26] have been consistently shown to
predict AKI in prior studies. Other studies have also
identified male sex [23], pregnancy [26], immunosup-
pression [19], hypertension [19], and co-infection [23] as
risk factors.
Not only was AKI common in our cohort, but most
patients with AKI progressed to the RIFLE category
of Failure (62.3%), similar to previous investigations
[19,23,25]. Rates of RRT utilization among all pH1N1
patients (15.1%) and among those developing AKI
(24.9%) were also relatively high and within the ranges
(7.6-23.8% and 22.0-44.0%, respectively) described previ-
ously [19,23,25,27]. These data contrast with large obser-
vational studies in non-pandemic populations that have
generally shown that only 4-6% of critically ill patients
receive RRT [38]. The higher rate of RRT utilization in
pH1N1-related critical illness may be explained by near
Table 7 Logistic regression model for hospital mortality in critically ill H1N1 patients
Variable Deaths Survivors Crude OR P
value
Adjusted OR P
value(n = 113) (n = 432) (95% CI) (95% CI)
H1N1 details, demographics, and comorbidities
Confirmed H1N1 104 (92.0) 364 (84.3) 2.16 (1.04-4.47) 0.04 1.59 (0.66-3.80) 0.30
Days of symptoms before hospitalization 5.5 (5.5) 5.2 (4.6) 1.01 (0.97-1.06) 0.55
Days of symptoms before ICU admission (n = 534, 110, 424) 7.2 (6.5) 6.2 (5.1) 1.03 (1.00-1.07) 0.08 1.04 (1.00-1.09) 0.06
Age (yr) 51.8 (15.6) 47.0 (14.6) 1.02 (1.01-1.04) 0.003 1.02 (1.00-1.04) 0.03
Female sex 55 (48.7) 234 (54.2) 0.80 (0.53-1.22) 0.30 1.00 (0.58-1.71) 0.99
Obesity 42 (37.2) 106 (24.5) 1.82 (1.17-2.82) 0.008 1.49 (0.85-2.62) 0.16
Diabetes mellitus 24 (21.2) 116 (26.9) 0.74 (0.45-1.21) 0.23
Chronic obstructive pulmonary disease 20 (17.7) 75 (17.4) 1.02 (0.60-1.76) 0.93
Alcohol abuse 9 (8.0) 64 (14.8) 0.50 (0.24-1.03) 0.06 0.77 (0.34-1.75) 0.54
Chronic kidney disease 15 (13.3) 33 (7.6) 1.85 (0.97-3.54) 0.06 1.35 (0.50-3.61) 0.55
Day 1 support, physiology, and laboratory parameters
APACHE II (n = 497, 101, 396) 25.0 (10.2) 20.0 (8.6) 1.06 (1.04-1.09) <0.0001 1.05 (1.01-1.08) 0.006
Invasive mechanical ventilation (n = 537, 111, 426) 82 (73.9) 289 (67.8) 1.34 (0.84-2.14) 0.22
Inotrope or vasopressor 52 (46.0) 186 (43.1) 1.13 (0.74-1.71) 0.57
Mean arterial pressure (mmHg) (n = 506, 103, 403) 75.1 (20.9) 74.2 (18.6) 1.02 (0.91-1.14) 0.70
PaO2/FiO2 (n = 480, 101, 379) 126 (84) 161 (99) 0.95 (0.93-0.98) 0.002 0.95 (0.92-0.99) 0.007
Creatinine (μmol/L) (n = 521, 109, 412) 159 (127) 115 (118) 1.03 (1.01-1.04) 0.002 1.001 (0.98-1.03) 0.95
Platelets (109/L) (n = 504, 105, 399) 151 (93) 196 (91) 0.94 (0.91-0.97) <0.0001 0.92 (0.89-0.96) <0.0001
Other
Acute kidney injury 85 (75.2) 244 (56.5) 2.34 (1.47-3.73) 0.0004 1.35 (0.74-2.48) 0.33
Categorical data are presented as n (%) and continuous data as mean (SD). Mortality status was missing for 17 patients. Heart rate, temperature, creatine kinase,
WBC, albumin, urea, and urine output were excluded due to a high proportion of missing data. SOFA score was excluded because it was highly collinear with
APACHE II (Pearson r = 0.6). For each variable, we specify n when it differs from the first row total. The final model included 414 patients and did not have
evidence of lack of goodness of fit (p = 0.49). ORs for continuous variables refer to an increment of 1 unit (age, APACHE II) or 10 units (mean arterial pressure,
PaO2/FiO2, platelets, creatinine).
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http://www.biomedcentral.com/1471-2369/14/123universal lung injury and higher acuity of illness in this
population, which may increase clinicians’ desire to miti-
gate fluid accumulation and attempt extracorporeal re-
moval of extravascular lung water. Other reasons for
variation in RRT utilization among pH1N1 patients may
include differences among regions and clinicians in the
perceived indications, utilization, and timing of initiation
of RRT.
Obesity has been found to be highly prevalent among
critically ill patients with pH1N1-related respiratory fail-
ure [2,5,39]. Whether obesity identifies poorer general
health characterized by cardiovascular disease, diabetes,
or maladaptive immune function, or contributes inde-
pendent risk due to alterations in pulmonary function
and diminished reserve, remains uncertain. Obesity was
associated with 3-fold higher odds of AKI, confirmed in
other studies [16,23,25].
Elevated creatine kinase (CK) has been implicated as a
contributing factor for AKI in pH1N1 [14,17,22,28].
Pettila et al. reported that 15.8% of AKI patients had CK
levels exceeding 5000 IU/L and found a trend ofincreasing CK levels with worsening AKI [26]. Demirjian
et al. found higher median CK levels in AKI compared
with non-AKI patients, with peak CK >2000 IU/L occur-
ring 22% of those with AKI and in no patient without
AKI [16]. In our study, CK levels were higher in AKI
compared with non-AKI patients; however, this differ-
ence was not statistically significant. While rhabdo-
myolysis may have a supporting causal role in AKI
among patients with pH1N1-related critical illness, the
etiology is likely to be multi-factorial. Recent data have
suggested that acute glomerular disease or active viral
replication in renal epithelial tissue may also contribute
[20,24].
From a health policy and planning perspective, antici-
pating the need for additional resources for a pandemic
such as pH1N1 [6], with a relatively high attack rate and
propensity for organ failure, is vital. In the case of
pH1N1, needs included additional ICU bed capacity,
availability of ventilators, and access to ECLS [9,10]. In
addition, pH1N1 patients had greater relative utilization
of RRT, highlighting the importance of expanded
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http://www.biomedcentral.com/1471-2369/14/123capacity for RRT services. Each of these technologies
would be expected to increase costs related to staffing,
disposables, and length of stay. This added resource bur-
den may contribute to decreased ICU bed availability
and hospital surge capacity during periods of heightened
demand and complicate triage decision-making during
future pandemics [40].
Conclusions
In summary, we describe the incidence and outcomes
associated with AKI complicating the course of pH1N1-
related critical illness in a large Canadian cohort. AKI
occurred in approximately 60% of patients, with the ma-
jority developing more advanced AKI, of whom a large
minority (24.9%) received RRT. Development of AKI
had important implications for utilization of health re-
sources, generally portending a significantly longer dur-
ation of ICU stay; however, it was not an independent
predictor of hospital mortality.
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